Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer

Tue, 05/17/2011 - 1:21pm

Study Meets Primary Endpoint by Significantly Improving Bone Metastasis-Free Survival for More Than Four Months

Up to 90 Percent of Men with Advanced Prostate Cancer Will Develop Bone Metastases

THOUSAND OAKS, Calif., May 17, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) today announced primary results of a pivotal Phase 3 trial (’147) demonstrating that XGEVA™ (denosumab) significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone.  Full results of the ‘147 study were presented for the first time today in a late-breaking plenary session at the American Urological Association (AUA) 2011 Annual Meeting in Washington, D.C.

Read the rest of this entry



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.